The development of therapeutic agents against SARS-CoV-2/COVID-19 faces numerous barriers and a multidisciplinary approach to evaluating drug efficacy and toxicity is essential. Experimental and preclinical data should be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combinations, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental factors for the rational identification of candidates and prioritization of clinical investigations. Although the identification of SARS-CoV-2 therapeutics is a priority, rigorous and transparent methodologies are crucial to ensure that accelerated research programmes result in high-quality and reproducible findings.

中文翻译：

---

鉴定SARS-CoV-2 / COVID-19治疗剂的挑战性途径。

抗SARS-CoV-2 / COVID-19的治疗剂的开发面临许多障碍，因此评估药物功效和毒性的多学科方法至关重要。实验和临床前数据应整合到综合分析中，其中药物效力，治疗开始时间，药物组合，全身和局部药物暴露的变异性以及短期和长期毒性是合理确定候选药物和药物的基本因素。优先进行临床研究。尽管识别SARS-CoV-2疗法是当务之急，但是严格而透明的方法对于确保加速研究计划产生高质量且可重复的发现至关重要。